Amoy Diagnostics Co., Ltd. (SHE:300685)

Market Cap	8.03B -11.1%
Revenue (ttm)	1.20B +8.0%
Net Income	361.26M +41.7%
EPS	0.90 +40.6%
Shares Out	391.13M
PE Ratio	22.82
Forward PE	21.40
Dividend	0.45 (2.02%)
Ex-Dividend Date	Jun 3, 2025

Volume	22,644,955
Average Volume	11,290,560
Open	22.17
Previous Close	22.33
Day's Range	20.13 - 22.17
52-Week Range	19.40 - 26.15
Beta	0.55
RSI	36.01
Earnings Date	Apr 16, 2026

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2008
• Employees: 1,144
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300685

Financial Performance

In 2025, Amoy Diagnostics's revenue was 1.20 billion, an increase of 8.01% compared to the previous year's 1.11 billion. Earnings were 361.26 million, an increase of 41.74%.